Cannabinoid Hyperemesis Syndrome. Prospective Multicenter Study of Patients Admitted to Adult Emergency Departments in Maine-et-Loire. (CANN-AIE)

Cannabinoid hyperemesis syndrome (CHS) is characterized by incoercible abdominal pain and vomiting in patients with chronic cannabis use. Patients are relieved by hot showers, an easily performed diagnostic test.

The prevalence of this syndrome in France is not well known. A single French study from 2021, carried out in two Marseille emergency departments, estimated a 1.6% prevalence of CHS (48 cases / 2848 patients) in patients consulting for acute abdominal pain with no etiology found over a 10-month period.

Cannabis is the most widely used illicit substance in France. France is also the second biggest cannabis consumer in Europe, with around 11% of the French population currently using the drug (use within the year).

Despite growing attention to CHS, the diagnosis and management of this syndrome remains difficult, with repeated visits to emergency departments often required before a diagnosis is made. What's more, once the diagnosis has been made, the severity of symptoms can lengthen the emergency room length of stay.

Main objective:

To estimate the incidence of cannabinoid hyperemesis syndrome among patients admitted on a first visit for abdominal pain and/or vomiting to the Maine et Loire emergency department.

Primary endpoint:

The incidence of cannabinoid hyperemesis syndrome among patients presenting with abdominal pain and/or vomiting, consulting adult emergency departments in Maine et Loire. Cannabinoid hyperemesis syndrome will be considered in all patients admitted for abdominal pain and/or vomiting, who are regular cannabis users (weekly use for more than 6 months declared by questionnaire) and in whom no other etiology is accepted after any additional examinations.

Research plan and procedure:

It is an observational, prospective, multi-center cohort study. Participation in the study is offered to any emergency room patient who meets all inclusion criteria and none of the non-inclusion criteria. Patients are included after reading the information note. Consent is obtained on a no-objection basis.

A questionnaire is given to participants via a QR code with an identification number generated by the investigating physician. This QR code opens an online questionnaire that the patient can fill in while in the emergency department. In the absence of access to the QR code (no cell phone), the questionnaire will be given to the participant in paper format by the investigating physician. It will be collected at the end of the inclusion visit.

Participants who have revealed cannabis use (at least 1 time per week for at least 6 months) via the questionnaire are followed up at 3 months (+/- 15 days) by telephone to assess the evolution of symptoms, any recurrences, medical treatment and whether or not cannabis has been withdrawn.

Inclusion criteria:

• Patients aged 18 to 65 years,
• Consulted an adult emergency department in Maine et Loire for abdominal pain and/or vomiting for the 1st time during the study period.

Non-inclusion criteria:

• Refusal to participate in the study
• Patient unable to answer the questionnaire (allophone, under guardianship, under protection, incapable of major age, in the process of legal proceedings)
• Pregnant women

Number of research participants:

At present, there are no data on the incidence of CHS in the French literature. In order to assess the number of subjects required, we made a projection based on the only French study to date. In this study, carried out in two departments in Marseille, the percentage of patients with CHS among those consulting the emergency department for acute abdominal pain was 1.6%. Thus, assuming that the proportion of the event will be identical to that of the study carried out in Marseille, i.e. 1.6%, it would be necessary to recruit 3,000 people with abdominal pain and/or vomiting to have around 50 patients with CHS.

Research duration:

Inclusion period: 12 months Duration of participation: 3 months +/- 15 days (for patients with CHS) Study duration: 15 months

Study Overview

• Status: Recruiting
• Conditions: Cannabinoid Hyperemesis Syndrome; D000096704

• Study Type: Observational
• Enrollment (Estimated): 3000

Contacts and Locations

• Study Contact: Name: Julien DENIS, Doctor; Phone Number: +33 2 41 53 30 30; Email: julien.denis@ch-saumur.fr

Study Locations

• France
  • Angers, France, 49100
    • Recruiting
    • Angers Centre Hospitalier Universitaire (CHU)
    • Contact: LUCILE RONZI, MD; Phone Number: 06 65 80 66 10; Email: lucile.bruere@chu-angers.fr
    • Contact: Recherche Clinique MU, MS; Email: Recherche-Clinique-MU@chu-angers.fr
    • Principal Investigator: LUCILE RONZI, MD
  • Cholet, France, 49300
    • Recruiting
    • Centre Hospitalier de Cholet
    • Contact: Caroline SOULIE-CHAVIGNON, MD; Phone Number: 02 41 49 69 85; Email: caroline.soulie-chavignon@ch-cholet.fr
    • Contact: Marion Jacob, MS; Email: marion.jacob@ch-cholet.fr
    • Principal Investigator: Caroline SOULIE-CHAVIGNON, MD
  • Saumur, France, 49400
    • Recruiting
    • Centre Hospitalier de Saumur
    • Contact: Julien DENIS, MD; Phone Number: 02 41 53 30 30; Email: julien.denis@ch-saumur.fr
    • Principal Investigator: Julien DENIS, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

At present, there are no data on the incidence of CHS in the French literature. In order to assess the number of subjects required, we made a projection based on the only French study to date. In this study, carried out in two departments in Marseille, the percentage of patients with CHS among those consulting the emergency department for acute abdominal pain was 1.6%. Thus, assuming that the proportion of the event will be identical to that of the study carried out in Marseille, i.e. 1.6%, it would be necessary to recruit 3,000 people with abdominal pain and/or vomiting to have around 50 patients with CHS.

Description

Inclusion Criteria:

• Patient aged 18 to 65 years,
• Consulted the Maine et Loire adult emergency department for abdominal pain and/or vomiting for the 1st time during the study period.

Exclusion Criteria:

• Refusal to participate in the study
• Patient unable to answer questionnaire (allophone, under guardianship, under protection, incapable of age, under legal proceedings)
• Pregnant women

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Patients with cannabinoid hyperemesis syndrome

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients with confirmed cannabinoid hyperemesis syndrome (CHS) among patients presenting with abdominal pain and/or vomiting, consulting adult emergency departments in Maine et Loire	The incidence of cannabinoid hyperemesis syndrome among patients presenting with abdominal pain and/or vomiting, consulting adult emergency departments in Maine et Loire. Cannabinoid hyperemesis syndrome will be considered in all patients admitted for abdominal pain and/or vomiting, who are regular cannabis users (weekly use for more than 6 months declared by questionnaire) and in whom no other etiology is accepted after further investigations.	Inclusion period will last 12 month and the whole study 15 month. Participation of each CHS positive patient is expected to last 3 month +/- 15 days.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Gender and age distribution of patients with cannabinoid hyperhaemesis syndrome (CHS)	Socio-demographic data for the CHS population: gender, age	Inclusion period will last 12 months and the whole study 15 months. Participation of each CHS positive patient is expected to last 3 months +/- 15 days.
Description and Distribution of CHS patients across clinical characteristics listing	Clinical characteristics of patients with CHS: frequency, type and location of abdominal pain, schedule of vomiting, improved by hot shower or not.	Inclusion period will last 12 months and the whole study 15 months. Participation of each CHS positive patient is expected to last 3 months +/- 15 days.
Describe cannabis use in patients with CHS: duration and frequency of use		Inclusion period will last 12 months and the whole study 15 months. Participation of each CHS positive patient is expected to last 3 months +/- 15 days.
Describe hospital management and therapies used for patients with CHS: additional tests performed, effectiveness of therapies (analgesics, antiemetics), patient pathway (discharge, short-term hospitalization unit, hospitalization).		Inclusion period will last 12 months and the whole study 15 months. Participation of each CHS positive patient is expected to last 3 months +/- 15 days.
Number of cannabis withdrawal attempts at 3 months in patients with CHS		3 months +/- 15 days
Number of patients with recurrence of symptoms (abdominal pain and/or vomiting) at 3 months		3 monts +/- 15 days
Number of patients reporting total cessation of cannabis use at 3 months post-inclusion		3 months +/- 15 days
Number of patients who need to consult again (emergency, general practitioner, other) at 3 months		3 months +/- 15 days
Number of patients reporting a consultation with an addictology referral at 3 months		3 months +/- 15 days

Collaborators and Investigators

• Sponsor: University Hospital, Angers
• Investigators: Principal Investigator: Julien DENIS, Doctor, Saumur Hospital Center

Study record dates

Study Major Dates

• Study Start (Actual): July 25, 2025
• Primary Completion (Estimated): October 31, 2026
• Study Completion (Estimated): October 31, 2026

Study Registration Dates

• First Submitted: October 24, 2024
• First Submitted That Met QC Criteria: October 24, 2024
• First Posted (Actual): October 28, 2024

Study Record Updates

• Last Update Posted (Estimated): August 28, 2025
• Last Update Submitted That Met QC Criteria: August 21, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Keywords: nausea; cannabis; abdominal pain; marijuana; Recurrent vomiting; compulsive hot bathing behavior
• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Mental Disorders; Signs and Symptoms, Digestive; Substance-Related Disorders; Chemically-Induced Disorders; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Cannabinoid Hyperemesis Syndrome; Abdominal Pain; Marijuana Abuse; Nausea; Vomiting
• Other Study ID Numbers: 49RC24_0175

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No